TUCSON, Ariz.--(BUSINESS WIRE)--ImaRx Therapeutics, Inc. (Nasdaq:IMRX) today announced it has received approval from the Data and Safety Monitoring Board (DSMB) to proceed with the second dose cohort in its TUCSON (Transcranial Ultrasound in Clinical SONoLysis) Phase I/II dose escalation study evaluating SonoLysis + tPA therapy in patients with acute ischemic stroke. SonoLysis + tPA therapy combines the Company’s proprietary MRX-801 microbubbles, ultrasound and the thrombolytic drug tPA.
